Thawing System Market to More Than Double, Hitting USD 1.15 Billion by 2031 as Cell Therapy Commercialisation Accelerates

Chicago, 03rd June 2025 – The global market for controlled thawing systems is projected to grow from USD 550 million in 2024 to USD 1.15 billion by 2031, achieving a CAGR of 11.0%, according to the latest analysis from Clearview Market Insights (CVMI).

“Every frozen dose of a cell therapy, every plasma unit used in trauma, and every bioprocess pool shipped between sites must be thawed flawlessly,” noted Dr. Miguel Carranza, Principal Analyst at CVMI. “Hospitals and biomanufacturers are replacing decades-old water baths with sensor-rich, closed systems that deliver consistency, traceability, and compliance.”

For the full report, visit https://clearviewmarketinsights.com/report-details/global-thawing-system-market/

Market Catalysts

Cell‑therapy surge – Commercial CAR-T and emerging iPSC-derived products require bag-compatible GMP thawers at both manufacturing and infusion sites, driving 13% annual growth in the segment.
Trauma‑care modernisation – Updated massive transfusion protocols recommend pre-staged AB plasma, and emergency departments are investing in dual-chamber rapid thawers.
Bulk drug‑substance logistics – Biopharma is progressing towards the frozen transport of monoclonal antibodies and viral vectors; closed thaw skids minimize contamination risk.
Regulatory pressure – EU GMP Annex 1’s 2023 revision explicitly discourages open water baths, thereby accelerating retrofit projects.
Digital traceability – Integration with LIMS and hospital EMR systems reduces manual logging errors by 90%, enhancing audit readiness.

Industry Leaders

Cytiva leads the leaderboard with a 19% share, driven by its VIA Thaw portfolio and newly launched CX-Pro platform, which accommodates bag volumes of up to 3 litres. Sartorius follows with a 15% share, providing fully integrated freeze-thaw skids for biologics manufacturing. Helmer Scientific dominates hospital plasma rooms, while Barkey and Sarstedt secure a share in compact benchtop and cord blood niches.

Regional Dynamics

North America – Holds 41 % share; BARDA’s $120 million Trauma Ready programme funds rapid thawer installations in 75 trauma centres.
Europe – IVDR and Annex 1 compliance spur replacement of legacy baths; Germany’s Cell‑Factory initiative subsidises GMP thaw equipment.
Asia‑Pacific – Fastest CAGR 14.6 %; China’s National Medical Products Administration (NMPA) approves five new CAR‑T products, while Japan deploys plasma thawers in disaster‑response caches.
Latin America & MEA – Growth fuelled by military blood programmes and NGO‑funded cell‑therapy trials.

Key Milestones 2024‑2026

Quarter	Event	Impact
Q4 2023	Cytiva debuts VIA Thaw CX‑Pro	40 % faster thaw for 3‑L bags
Q1 2024	Sartorius opens Göttingen thaw test centre	Accelerates tech transfer for CDMOs
Q2 2024	Helmer launches cloud‑connected Bio‑Therm	Enables predictive maintenance alerts
Q4 2024	Barkey wins FDA 510(k) for Plasma‑Therm Duo	First dry‑heat plasma thawer cleared under IEC‑60601‑3rd ed
Q1 2025	BioLife acquires Delta T	Creates end‑to‑end frozen transport + thaw solution

Technology Trends

IoT‑Enabled Thaw Analytics – Real‑time temperature curve monitoring slashes deviation investigations.
Cassette‑Based, Single‑Use Inserts – Sterile, bag‑agnostic cassettes eliminate cross‑contamination, critical for autologous therapies.
Energy‑Optimised Heating Elements – Reduce operating costs by 18 % compared with legacy dry‑heat units.
AI‑Adaptive Ramp Profiles – Machine‑learning algorithms adjust ramp rates based on fill volume and bag geometry, improving cell viability by up to 8 %.

Looking Ahead to 2031

2026 – 60 % of new cell‑therapy cleanrooms install closed, cassette‑ready thawers.
2027 – Automated plasma‑thaw cabinets with RFID integration become standard in Level‑1 trauma centres.
2028 – Bulk‑freeze‑thaw modules with reversible flow paths adopted by 45 % of monoclonal‑antibody plants.
2029 – Cloud analytics predict element replacement, cutting unplanned downtime 30 %.
2030 – Harmonised ISO standard for bag‑thaw cassette dimensions published, easing supply‑chain constraints.
2031 – Over 75 % of frozen CGT doses worldwide are thawed on IoT‑connected, validated systems.

Expert Insight: “Validated thawers are now as mission‑critical as cryofreezers,” said Dr. Lisa Ofori‑Addo, Head of Cell‑Therapy Operations at St. Jude’s. “The ability to document every second of the thaw unlocks smoother regulatory audits and higher patient confidence.”

 

 

For more insights, visit https://clearviewmarketinsights.com/

 

About Clearview Market Insights:

Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.

 

Media contact:

Bhavani K

Marketing and Sales Head

ClearView Market Insights

Mail: sales@clearviewmarketinsights.com

Phone: +1 917-993-7369